Effects of systemic chemotherapy on the liver.

作者: Giuliano Ramadori , Silke Cameron

DOI: 10.1016/S1665-2681(19)31651-5

关键词: PharmacologySteatohepatitisCombination chemotherapyMedicineContext (language use)MetabolismParenchymatous organChemotherapyGenetic predispositionTolerability

摘要: The liver is the largest parenchymatous organ of body and central for intermediate metabolism. Its close contact to portal blood streaming back from gut systemic circulation a prerequisite various processes ongoing on cellular level. spatial relationship hepatocytes with different structures liver, such as fenestrated sinusoidal endothelial cells, Kupffer bile canaliculi important organization performance metabolism nutrients (proteins, glucose fatty acids), clearance toxic or infectious agents, metabolic detoxification excretion waste products. administration chemotherapy challenge tight regulation balance these processes. As most drugs tend be lipophilic, they are readily taken up by liver. Under chemotherapy, 85% patients develop steatosis. Steatohepatitis more serious event, especially if accompanied an increase in bilirubin levels. Modern understanding efficacy, safety tolerability combination has increasingly include individual context patient, age, gender, nutritional status, underlying diseases, genetic predisposition, well cross-reactivity drugs. This review tries capture effects focus chemotherapeutical compounds used treatment gastrointestinal cancers.

参考文章(78)
MacLellan A, King Jj, Khan A, Hill Jm, Loeb E, Hill No, Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. Cancer chemotherapy reports. ,vol. 59, pp. 647- ,(1975)
Keith Robinson, Louis Lambiase, JianJun Li, Carmela Monteiro, Michael Schiff, Fatal cholestatic liver failure associated with gemcitabine therapy. Digestive Diseases and Sciences. ,vol. 48, pp. 1804- 1808 ,(2003) , 10.1023/A:1025415616592
J. Larsson, I. Ihse, S. Skullman, Influence of malnutrition on regeneration and composition of the liver in rats. Acta chirurgica Scandinavica. ,vol. 156, pp. 717- 722 ,(1990)
A. Kirn, D.L. Knook, R.S. McCuskey, L. Bouwens, E. Wisse, K. Wake, K. Decker, Cell Biology and Kinetics of Kupffer Cells in the Liver International Review of Cytology. ,vol. 118, pp. 173- 229 ,(1989) , 10.1016/S0074-7696(08)60875-X
Robert B. Diasio, Martin R. Johnson, Dihydropyrimidine Dehydrogenase: Its Role in 5-Fluorouracil Clinical Toxicity and Tumor Resistance Clinical Cancer Research. ,vol. 5, pp. 2672- 2673 ,(1999)
Robbert J. van Alphen, Alex Sparreboom, Kees Nooter, Ron H. J. Mathijssen, Walter J. Loos, Gerrit Stoter, Jaap Verweij, Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clinical Cancer Research. ,vol. 7, pp. 2182- 2194 ,(2001)
Alan P. Venook, Merrill J. Egorin, Gary L. Rosner, Donna Hollis, Sridhar Mani, Michael Hawkins, John Byrd, Raymond Hohl, Daniel Budman, Neal J. Meropol, Mark J. Ratain, Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565 Journal of Clinical Oncology. ,vol. 18, pp. 2780- 2787 ,(2000) , 10.1200/JCO.2000.18.14.2780
S P Joel, R Shah, P I Clark, M L Slevin, Predicting etoposide toxicity: relationship to organ function and protein binding. Journal of Clinical Oncology. ,vol. 14, pp. 257- 267 ,(1996) , 10.1200/JCO.1996.14.1.257
C. J. Pérez Sánchez and F. Sánchez M. I. Lucena, R. Camargo, R. J. Andrade, Comparison of two clinical scales for causality assessment in hepatotoxicity Hepatology. ,vol. 33, pp. 123- 130 ,(2001) , 10.1053/JHEP.2001.20645